XNW-27011

N/A

Report date: 2026/02/26 20:00:22

Base Information

Drug NameXNW-27011
Drug Alias NameXNW-27011
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)
Mechanisms of ActionAnti-CLDN18
TargetsClaudin-18 splice variant 2
Therapy Area/IndicationsGastroesophageal Junction NeoplasmsSolid tumoursCarcinoma, Non-Small-Cell Lung +[8] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesEvopoint Biosciences Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesShanghai Cigna Biotech Pharmaceutical Co LtdAstellas Pharma IncEvopoint Biosciences Co Ltd
Inactive CompaniesN/A
Active IndicationsGastroesophageal Junction NeoplasmsSolid tumoursCarcinoma, Non-Small-Cell Lung +[8] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A